Daniel P. Silver MD, PhD
Leader, Breast Program, Sidney Kimmel Cancer Center
- Leader of the breast cancer program at the Sidney Kimmel Cancer Center at Thomas Jefferson University
- Developed a biomarker test to predict chemotherapy responsiveness in triple-negative breast cancer
Daniel P. Silver, MD, PhD, is a board certified medical oncologist and cancer researcher. He is the leader of the breast cancer program at the Sidney Kimmel Cancer Center at Thomas Jefferson University, where he also directs research in medical oncology. He developed a biomarker test to predict chemotherapy responsiveness in triple-negative breast cancer, and works to find new and better treatments for this type of disease.
Dr. Silver’s lab focuses on finding new targets for cancer treatment, identifying cancer-related genes and understanding how they work, and developing biomarker tests to predict how well medicines will work in individuals. The lab has also researched the BRCA1 and BRCA2 gene mutations and DNA repair.
Dr. Silver played a significant role in a clinical trial that suggested platinum chemotherapy would be effective in triple-negative breast cancer, and he co-led a project that resulted in a new predictive biomarker test, the HRD Assay, which helps identify when chemotherapy will work well against cancer. Recently, his lab discovered a new cancer-related gene that is amplified and overexpressed in one-third of triple-negative breast cancers and which may be a target for new therapies for this subtype of breast cancer.
Dr. Silver is a member of LBBC's Medical Advisory Board.